Sandostatin

Entity type image
Type: Product
Name: Sandostatin
First reported May 02 2013 - Updated May 03 2013 - 1 reports
Novartis AG
Novartis AG

Novartis Could Face Exclusion From Federal Health Care Programs If...

U.S. government's intervention in two whistleblower lawsuits against Novartis, alleging kickbacks and other frauds, could have serious implications for the pharmaceutical giant, according to members of the . http://www.quitamteam.com; e-mail: QuiTamT ... [Published PRWeb - May 02 2013]

Quotes

...John Mininno, Esquire commented as follows: "We are pleased that the United States has decided to intervene in this matter and we look forward to working with the government in pursuing this important case."
U.S. Joins Shepherd, Finkelman, Miller & Shah, LLP Whistleblower Lawsuit Against Novartis Pharmac ... [Published Pharmacy Choice - May 09 2013]
"Novartis pervasive business practices to allegedly fraudulently market numerous drugs including Lotrel, Valturna, Starlix, Tekturna, Diovan, and Exforge, cost taxpayers hundreds of millions of dollars said Eric L Young, Esquire, Young Law Group, who, with James E Miller, Esquire, of Shepherd, Finkelman, Miller, and Shah, LLP, and John Minnino, Esquire, of Minnino Law Offices, is representing the whistleblower, former Novartis sales representative, Oswald Bilotta."
United States Joins Whistleblower Lawsuit Against Novartis P. . . [Published Equities.com - Apr 26 2013]
"Novartis' pervasive business practices to allegedly fraudulently market numerous drugs including Lotrel, Valturna, Starlix, Tekturna, Diovan, and Exforge, cost taxpayers hundreds of millions of dollars" said Eric L Young, Esquire, Young Law Group, who, with James E Miller, Esquire, of Shepherd, Finkelman, Miller, and Shah, LLP, and John Minnino, Esquire...
United States Joins Whistleblower Lawsuit Against Novartis Pharmaceuticals [Published Individual.com - Apr 26 2013]

More Content

All (8) | News (6) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
FDA is Asked to Deviate From ANDA “Exception Ex... [Published FDA Law Blog - May 21 2013]
U.S. Joins Shepherd, Finkelman, Miller & Shah, ... [Published Pharmacy Choice - May 09 2013]
Novartis Could Face Exclusion From Federal Heal... [Published PRWeb - May 02 2013]
United States Joins Whistleblower Lawsuit Again... [Published Equities.com - Apr 26 2013]
United States Joins Whistleblower Lawsuit Again... [Published Individual.com - Apr 26 2013]
U.S. Joins Shepherd, Finkelman, Miller & Shah, ... [Published Street Insider - Apr 26 2013]
Now Available: Acromegaly - Pipeline Review, H1... [Published Live-PR.com - Apr 19 2013]
Deals Of The Week Wonders What Merck's Latest B... [Published The IN VIVO Blog - Feb 22 2013]
1
In Focus
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA is Asked to Deviate From ANDA “Exception Ex... [Published FDA Law Blog - May 21 2013]
By Kurt R. Karst –A Citizen Petition (Docket No. FDA-2013-P-0203) submitted to FDA earlier this year raises an issue that comes up from time to time – although not typically in a public forum – about the Agency’s so-called “exception excipient” regulations ...
Deals Of The Week Wonders What Merck's Latest B... [Published The IN VIVO Blog - Feb 22 2013]
Ever since Merck jumped into the biosimilar field in 2008 with a ferocious go get ’em attitude more fitting of an NFL tackle than a big pharma, we’ve been following their progress – and then lack of progress – closely. Back when most pharmaceutical ...
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.